Three years ago, a writer for Wired magazine went hunting for Medtech’s Bigfoot.
The mysterious person had done what was seemingly impossible: create an artificial pancreas that can both detect drops in insulin and order the injection of replacement.
The widely read article clearly demonstrated two undeniable facts. First, patients with type 1 diabetes are not satisfied with their current solutions that are light on data and heavy on people managing their own disease. Second, the tale of a father hacking a glucose monitor and insulin delivery device with a cell phone signaled the integral role mobile technology and Big Data will play in disease management going forward.
Those truths led to the creation of Bigfoot Biomedical, a privately held start-up that’s building off the homegrown hack performed by Bryan Mazlish, the so-called Bigfoot who now serves as chief product officer for the company.
In this Medtech Talk Podcast, Jeffrey Brewer, CEO and president of Bigfoot Biomedical, explains the origins of the start-up. Brewer, like Mazlish, steered his career toward diabetes management when the disease struck his family.
Brewer explains how his son’s diagnosis – and at least one near-fatal experience – pushes him forward to ensure Bigfoot leads the class of next-generation devices that may someday come close to creating a cure for this dreaded disease.